Equity Profile

ELVN

Enliven Therapeutics, Inc.

Health CarePharmaceuticals$2.1B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Enliven Therapeutics, Inc. (ELVN) Beats on EPS, Stock Down 2.21%

Metric	Actual	Expected	Surprise
EPS	-$0.38	N/A	+13.64%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Enliven Therapeutics, Inc. (ELVN) Beats on EPS, Stock Down 2.21%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	-$0.38	N/A	+13.64%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Enliven Therapeutics reported a narrower loss per share than expected, which is a positive sign for investors. However, the stock fell by 2.21% in reaction, indicating that investors may have had concerns about other aspects of the company's performance or future outlook. The lack of revenue data and guidance may have contributed to the stock's decline.

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes in various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes in various health conditions. With a market cap of $2 billion, its performance is closely watched in the healthcare sector, especially as the industry navigates ongoing challenges and opportunities in drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In the last quarter, Enliven reported an EPS of -$0.48, missing estimates by 14.29%. The stock reacted negatively, dropping 2.54% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors are particularly focused on how the company will manage its R&D investments.

Bull Case

If Enliven can demonstrate significant progress in its drug pipeline and achieve better-than-expected EPS, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to show progress in its R&D efforts or reports a larger-than-expected loss, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

The market will closely watch for updates on the pipeline as it directly impacts future revenue potential and investor confidence.

How much is the company planning to invest in R&D this quarter?

R&D spending is crucial for growth in the pharmaceutical sector, and any changes could indicate shifts in strategy or financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Enliven's drug pipeline to yield positive results, particularly given the recent uptick in R&D focus.

Supporting Evidence

Options are pricing a 13.03% move, suggesting higher volatility than the stock has historically shown.

The company's recent history of beating EPS estimates could indicate a turnaround in performance.

Key Risk

If the company reports an EPS loss narrower than expected, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage its R&D spending while improving its financial performance.

Bull Confirmed If

Demonstrating a significant reduction in EPS loss, aiming for -$0.30 or better, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.03%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±13.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

64.2%

Calls (700)P/C Ratio: 1.71Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.9%, with a raw directional average of +0.3% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$238,352.42

5,000 sh

1 insider

Net

$238,352.42

Net selling

Most Active Insiders· 3 open-market trades

CHIEF MEDICAL OFFICERCollins Helen Louise
$238,352.42

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests a potential stock increase of around 3.36%, confirming confidence in its drug pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement, reflecting ongoing uncertainty in the market.

Miss

A miss could lead to a decline of around 1.62%, indicating investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any clinical trial results.
2Details on R&D spending plans for the upcoming quarter.
3Management's outlook on market conditions and competition.
4Any commentary on partnerships or collaborations in development.
5Insights into operational efficiencies and cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BMRNReported

BioMarin Pharmaceutical Inc.

RecapView

May4

PLTRReported

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies to improve patient outcomes in various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In the last quarter, Enliven reported an EPS of -$0.48, missing estimates by 14.29%. The stock reacted negatively, dropping 2.54% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of both beating and missing EPS estimates. Investors are particularly focused on how the company will manage its R&D investments.

Bull Case

If Enliven can demonstrate significant progress in its drug pipeline and achieve better-than-expected EPS, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to show progress in its R&D efforts or reports a larger-than-expected loss, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

The market will closely watch for updates on the pipeline as it directly impacts future revenue potential and investor confidence.

How much is the company planning to invest in R&D this quarter?

R&D spending is crucial for growth in the pharmaceutical sector, and any changes could indicate shifts in strategy or financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Enliven's drug pipeline to yield positive results, particularly given the recent uptick in R&D focus.

Supporting Evidence

Options are pricing a 13.03% move, suggesting higher volatility than the stock has historically shown.

The company's recent history of beating EPS estimates could indicate a turnaround in performance.

Key Risk

If the company reports an EPS loss narrower than expected, it could shift sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage its R&D spending while improving its financial performance.

Bull Confirmed If

Demonstrating a significant reduction in EPS loss, aiming for -$0.30 or better, would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±13.03%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±13.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

64.2%

Calls (700)P/C Ratio: 1.71Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.9%, with a raw directional average of +0.3% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$238,352.42

5,000 sh

1 insider

Net

$238,352.42

Net selling

Most Active Insiders· 3 open-market trades

CHIEF MEDICAL OFFICERCollins Helen Louise
$238,352.42

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests a potential stock increase of around 3.36%, confirming confidence in its drug pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement, reflecting ongoing uncertainty in the market.

Miss

A miss could lead to a decline of around 1.62%, indicating investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any clinical trial results.
2Details on R&D spending plans for the upcoming quarter.
3Management's outlook on market conditions and competition.
4Any commentary on partnerships or collaborations in development.
5Insights into operational efficiencies and cost management strategies.